Method for extracting naringenin from Chinese medicament chinaroot greenbrier and application thereof

A technology of naringenin and sarsaparilla, which is applied in the field of extracting naringenin, can solve the problems of decreased nerve transmission speed, increased osmotic pressure, and complications of diabetes, and achieves remarkable effects, clear structure, and favorable quality control effects

Inactive Publication Date: 2008-09-17
SHANGHAI UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the one hand, the accumulation of sorbitol will cause an increase in osmotic pressure, resulting in tissue (vascular, nerve, kidney, retina, lens, etc.) edema, leading to changes...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for extracting naringenin from Chinese medicament chinaroot greenbrier and application thereof
  • Method for extracting naringenin from Chinese medicament chinaroot greenbrier and application thereof
  • Method for extracting naringenin from Chinese medicament chinaroot greenbrier and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Separation, extraction and purification of monomers

[0018] Weigh 1000g of Smilax sarsaparillae and extract it with 70% ethanol to obtain 78.32g of extract, which is then extracted successively with petroleum ether and ethyl acetate, and the ethyl acetate phase is 31.26g. Phase chromatography, mobile phase is ethyl acetate-methanol (9: 1), fractional collection, 200mL / bottle, 28 bottles are collected in total, and No. 4-12 bottles are combined and concentrated, and then put on a 200-300 mesh silica gel column ( 4.5×50cm), mobile phase chloroform-methanol (100:1) to chloroform-methanol (4:1) gradient elution, fractional collection, 200mL / bottle, 16 bottles were collected, 12, 13 bottles were concentrated, precipitated out . The precipitate can be subjected to single-gradient column chromatography depending on the purity, and the reference elution system is chloroform-methanol (9:1). Depending on the results of thin layer chromatography combined with ultravi...

Embodiment 2

[0021] Example 2: Structural Identification of Monomers

[0022] White needle-like crystals (methanol). Soluble in methanol, ethanol. Molecular weight is 272, molecular formula C 15 h 12 o 5 . . ESI-MSm / z: 273[M-H] + . 1 H NMR (CD 3 OD) δ: 7.36 (2H, d, J = 8.5, C 2 ’-H, C 6 '-H), 6.82 (2H, d, J=2.7, 9.4, C 3 ’-H, C 5 '-H), 5.98 (1H, d, J=2.1, C 6 -H), 5.35 (1H, dd, J=3.0, 13.5, C 2 -H), 3.05 (1H, d, J=14.5, C 3 -H α ), 2.78 (1H, dd, J=3.0, 14.6, C 3 -H β ). 13 C NMR (CD 3 OD) δ: 79.1 (C-2), 42.6 (C-3), 196.3 (C-4), 164.1 (C-5), 127.6 (C-6), 167.1 (C-7), 94.8 (C- 8), 163.5(C-9), 101.9(C-10), 129.7(C-2'), 115.0(C-3'), 157.6(C-4'), 115.0(C-5'), 127.6 (C-6').

[0023] In summary, the compound is 3(S)-5,7,4'-trihydroxydihydroflavone, namely naringenin (Naringenin, Nar).

Embodiment 3

[0024] Embodiment three: the inhibitory activity of monomer to α-glucosidase

[0025] Add 0.76mL of pH6.8 potassium phosphate buffer solution, 20μL of 1mg / mL reduced glutathione, 10μL of 0.0167U / mL α-glucosidase to the test tube in turn, after incubation at 37°C for 10min, add 10μL of 0.116M PNPG, Scan at a wavelength of 400nm for 6min to record the change of absorbance. The definition of α-glucosidase activity unit: under the conditions of pH 6.8 and temperature 37°C, at 400nm, the absorbance value rises by 0.1 per minute as an activity unit.

[0026] Add potassium phosphate buffer, 20 μL 1mg / mL reduced glutathione, 10 μL 0.0167U / mL α-glucosidase, and a certain amount of inhibitor solution (1mg / mL, prepared with potassium phosphate buffer), 37°C After incubation for 10 minutes, add 10 μL of 0.116M PNPG, scan at 400 nm wavelength for 6 minutes, and record the change of absorbance. The total reaction system is 0.8 mL. Definition of activity unit of α-glucosidase inhibitor: un...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method and application of extracting naringenin from the Chinese traditional medicine, bamboo brier. The method includes pulverizing the Chinese traditional medicine bamboo brier, cold soaking in 70% ethanol to obtain the leach solution, concentrating to obtain the extract, suspending in distilled water, extracting and defatting with the petroleum ether, and extracting the defatted water phase with ethyl acetate; performing chromatography on the ethyl acetate phase in a silica gel column, eluting with ethyl acetate-methanol system (9:1), collecting the eluent part by part, combining and concentrating the frontmost segment, gradient eluting with chloroform: methanol with the silica gel column, collecting in a sectional manner, and concentrating to separate the precipitate; and repeatedly purifying with column, and re-crystallizing with methanol to obtain white needle crystal. In the method, pure 3(S)-5,7, 4'-trihydroxy flavanone, i.e., naringenin, extracted from the Chinese traditional medicine bamboo brier, has aldose reductase and Alpha-glucosidase inhibiting activity and is effective in adjusting and controlling glucose absorption of small intestine and preventing and treating diabetic complication. The purified monomer has clear structure and remarkable effect, which facilitates the quality control and the Chinese traditional medicine modernization process; and the naringenin can be further chemically modified to deeply study occurrence and development mechanism of diabetes and complication thereof so as to develop the new drug for treating diabetes and complication thereof.

Description

technical field [0001] The invention relates to a method and application of extracting naringenin from Chinese medicine sarsaparilla. Background technique [0002] Diabetic complications are mostly caused by long-term hyperglycemia, hyperlipidemia, blood hypercoagulation, hyperviscosity, and endocrine disorders. Common complications include: diabetic ketoacidosis, nonketotic hyperosmolar coma, diabetic lactic acidosis, diabetic heart disease, diabetic cerebrovascular disease, diabetic extremity gangrene, diabetic neuropathy, diabetes Diabetic nephropathy, diabetic retinopathy, and various infections caused by diabetes, among which diabetic macroangiopathy and microangiopathy are the most common. These complications are often more serious than diabetes itself, leading to significantly increased morbidity and mortality from certain diseases. At present, it is believed that diabetic complications are related to the following factors: (1) Absolute or relative lack of insulin. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D311/32A61K31/353A61P3/10A61K36/896
Inventor 沈忠明施堃殷建伟沈莉娟
Owner SHANGHAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap